(1 - 5 von 5
)
PropThink: VEN-307 is Ideal for a Small Company to Launch, says...
www.finanznachrichten.de
... "trifecta of anal fissure endpoints" with its lead candidate VEN In a 465 patient Phase III trial, CEO Russel Ellison says the company saw.
sortiert nach Relevanz / Datum